vaccine

58.3% would like stricter Covid-19 measures while 84% want to work from home

At-risk people and those working with vulnerable groups will be first to receive shots

Dealing with outbreaks, vaccines, gloomy economic prospects and an upcoming snap election among main hot topics

Janssen tests to be held in Madrid and Santander with 190 people and first results may be known "in a month"

Salvador Illa says EU relying on Oxford vaccine, but still waiting for "last stages of verification"

Fundraising initiatives, volunteering, and daily rounds of applause show people’s best sides in these trying times

First ever congress in Catalan capital explores ways of tackling disease that claimed the lives of 800,000 children last year

A clinical trial of a vaccine has proved, for the first time ever, that the immune system of those infected with AIDS can be re-educated in order to control the virus for long periods of time and without taking anti-retroviral drugs. In particular, 5 of the 13 patients whom participated in the trial and stopped their treatment achieved control of the virus for 5, 13, 17, 20 and 27 weeks respectively. The research, which is still ongoing, is being developed in different hospitals in Barcelona and Badalona and is directed by the IrsiCaixa AIDS Research Institute, a leading centre for research into the eradication of HIV/AIDS and related diseases, and the Fight AIDS Foundation, a non-profit organisation that is dedicated to healthcare, research and education in the field of HIV/AIDS, created by Doctor Bonaventura Clotet in 1992.

Researchers at the Hospital Germans Trias in Badalona (Greater Barcelona) have taken an important step toward creating a vaccine for Type 1 diabetes, which currently has no cure. The discovery, published in the scientific journal 'Plos One', consists of the preparation of nanoparticles in the laboratory that, once introduced into the body, slow down the destruction of beta cells (whose primary function is to store and release insulin). With Type 1 diabetes, the body’s immune system attacks these insulin-producing cells located in the pancreas and destroys them. Currently, to combat the disease, patients must take insulin injections. In recent years, Catalonia has become a global hub for biomedical investigation, developing cutting-edge research initiatives and participating in leading international projects. With just 0.1% of the world’s population, Catalonia accounts for nearly 1% of global scientific production and attracts 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants.

On Wednesday the World Health Organisation (WHO) appointed Barcelona-based researcher Pedro Alonso as the new Director of its Global Malaria Program. Alonso is a key figure in the global fight against malaria and has lead research into a vaccine to combat the life-threatening illness. He has been involved with WHO since 2011, when the organisation appointed him as the Chair of the GTS Steering Committee on the Global Technical Strategy on Malaria. Alonso is currently the Director of the Barcelona Institute for International Health Research. He is also the Head of the Department of International Health and Tropical Medicine at Barcelona's Hospital Clínic and a lecturer at Barcelona University. The physician is due to start his new position in October and is expected to give his formal recommendation on the strategy against malaria in the first quarter of 2015.

At the HIV Vaccine World Congress, which is taking place in Barcelona between the 7^th and 10^th October, Catalan researchers presented a vaccine prototype that has proven to be effective in clinical studies conducted with mice and monkeys. The vaccine stimulates the creation of antibodies and attacks infected cells. The prototype has been created by the Catalan programme to develop a vaccine against HIV, HIVACAT. According to the programme’s Scientific Director, Christian Brander, the vaccine could eventually also be used as a therapeutic treatment.

Christian Brander is a researcher at the IrsiCaixa AIDS Research Institute and Scientific Director of HIVACAT, the programme for the development of a HIV vaccine. He graduated from the University of Bern in 1994 with a PhD in Immunology and has spent 13 years at Harvard University focusing on cellular immunity to viral infections.

The vaccine MVA-B against HIV gets a 90% immune response in its first test with humans. In addition, after a year, the vaccine proves to still be effective in 85% of the individuals. The vaccine is still a prototype but it shows a promising perspective. Soon it will be tested as well as a therapeutic vaccine, for people already infected with HIV-AIDS. The vaccine has been developed by the Spanish High Council of Scientific Research (CSIC), in collaboration with Barcelona’s Hospital Clínic and by Madrid’s Hospital Gregorio Marañón.